Glaucoma News and Research

Latest Glaucoma News and Research

NIH-funded analysis identifies three genes that contribute to most common form of glaucoma

An analysis funded by the National Eye Institute (NEI), part of the National Institutes of Health, has identified three genes that contribute to the most common type of glaucoma. The study increases the total number of such genes to 15.

12 Jan 2016

Head-down yoga positions fatal for glaucoma patients

Glaucoma patients may experience increased eye pressure as the result of performing several different head-down positions while practicing yoga, according to a new study published by researchers at New York Eye and Ear Infirmary of Mount Sinai in the journal PLOS ONE.

11 Jan 2016

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.

22 Dec 2015

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

Bio Light Israeli Life Sciences Investments Ltd., an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that its IOPtiMate system for the treatment of glaucoma has been approved by the Canadian Medical Devices Bureau, allowing the Company to commercialize the surgical system in Canada.

21 Dec 2015

BioLight announces first sale of IOPtiMate system in Portugal

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate system to a medical center located in Portugal.

8 Dec 2015

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.

8 Dec 2015

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

OphthaliX Inc., a clinical-stage company focused on developing therapeutic products for the treatment of ophthalmic disorders and a subsidiary of Can-Fite BioPharma Ltd., announced today that it has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.

7 Dec 2015

Johns Hopkins researchers develop method to turn stem cells into retinal ganglion cells

Johns Hopkins researchers have developed a method to efficiently turn human stem cells into retinal ganglion cells, the type of nerve cells located within the retina that transmit visual signals from the eye to the brain. Death and dysfunction of these cells cause vision loss in conditions like glaucoma and multiple sclerosis.

1 Dec 2015

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs.

27 Nov 2015

BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight Life Sciences Investments, a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, announced today that it has entered into a joint financing agreement (the "Agreement") with two Asia-based venture capital firms (the "New Investors"), pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight's IOPtima Ltd. subsidiary via a private placement.

25 Nov 2015

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization for NUMIENT (Levodopa and Carbidopa), a modified-release oral capsule formulation for the symptomatic treatment of adult patients with Parkinson's disease.

25 Nov 2015

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

In a randomized clinical trial of more than 300 participants, researchers from Johns Hopkins and elsewhere have found that ranibizumab — a drug most commonly used to treat retinal swelling in people with diabetes — is an effective alternative to laser therapy for treating the most severe, potentially blinding form of diabetic retinal disease. Results of the government-sponsored study also show that the drug therapy carries fewer side effects than the currently used laser treatment.

17 Nov 2015

AAO recognizes outstanding eye physicians and surgeons for innovation in patient care

The American Academy of Ophthalmology will pay tribute to outstanding eye physicians and surgeons who have made significant achievements in various areas of the profession. These range from scientific innovation and humanitarian service to education and advocacy. The honorees will be recognized AAO 2015, the Academy's 119th annual meeting in Las Vegas.

13 Nov 2015

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

In a major scientific breakthrough, a drug used to treat Parkinson's and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.

10 Nov 2015

Charles Bonnet syndrome: an interview with Dr. Dominic ffytche

Charles Bonnet syndrome is the name we give to the visual hallucinations associated with eye disease. There are lots of different causes of visual hallucinations. Many different medical problems and medications can cause them, but, when the cause is eye disease, it's referred to as Charles Bonnet Syndrome after Charles Bonnet, who was a natural philosopher in the 18th century.

2 Nov 2015

Saint Louis University ophthalmologist offers tips to manage night vision issues

Owls and cats are at an advantage as the days get darker, but humans may notice their vision takes a hit during their evening commute home as daylight hours shrink.

31 Oct 2015

Q BioMed signs definitive license agreement with Mannin Research

Q BioMed Inc., a biotechnology acceleration company is pleased to announce it has signed a definitive license, with the option to acquire, the platform technology assets of Mannin Research Inc.

30 Oct 2015

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Novartis announced today that the US Food and Drug Administration has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is not indicated to treat asthma or sudden symptoms of COPD.

30 Oct 2015

Latinos with African ancestry at higher risk for glaucoma

Latinos with African ancestry are at a higher risk for high pressure within the eye, a condition that if untreated can damage the optic nerve and impair vision, according to a report in the journal Ophthalmology.

22 Oct 2015

Gait analysis could lead to reduced falls, injuries in people with glaucoma

Washington State University researchers have developed a way to carefully analyze a person's gait with sensors, an innovation that could lead to reduced falls and injuries in people with glaucoma, the second leading cause of blindness in the United States.

22 Oct 2015

Glaucoma News and Research

Latest Glaucoma News and Research

NIH-funded analysis identifies three genes that contribute to most common form of glaucoma

Head-down yoga positions fatal for glaucoma patients

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

BioLight announces first sale of IOPtiMate system in Portugal

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

OphthaliX completes patient enrollment in CF101 Phase II trial for treatment of glaucoma

Johns Hopkins researchers develop method to turn stem cells into retinal ganglion cells

Can-Fite BioPharma reports financial results, provides updates on drug development programs

BioLight signs joint financing agreement with two Asia-based venture capital firms

Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Researchers find ranibizumab drug as effective alternative to laser therapy for treating diabetic retinopathy

AAO recognizes outstanding eye physicians and surgeons for innovation in patient care

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

Charles Bonnet syndrome: an interview with Dr. Dominic ffytche

Saint Louis University ophthalmologist offers tips to manage night vision issues

Q BioMed signs definitive license agreement with Mannin Research

Novartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD patients

Latinos with African ancestry at higher risk for glaucoma

Gait analysis could lead to reduced falls, injuries in people with glaucoma

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Glaucoma News and Research

Latest Glaucoma News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in